argenex SE $ARGX Shares Sold by Natixis Advisors LLC

Natixis Advisors LLC lessened its holdings in shares of argenex SE (NASDAQ:ARGX) by 8.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,500 shares of the company’s stock after selling 2,003 shares during the quarter. Natixis Advisors LLC’s holdings in argenex were worth $18,921,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in ARGX. Capital World Investors boosted its position in argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after purchasing an additional 8,422 shares during the period. M&T Bank Corp lifted its position in shares of argenex by 20,977.7% during the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares in the last quarter. Bank of America Corp DE lifted its position in shares of argenex by 1.9% during the third quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock worth $252,525,000 after purchasing an additional 6,259 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of argenex by 570.3% during the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Ratings Changes

ARGX has been the topic of a number of recent research reports. Wells Fargo & Company boosted their target price on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Glj Research raised shares of argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. HC Wainwright lifted their price objective on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Finally, Robert W. Baird upped their target price on argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a research report on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,019.50.

argenex Trading Up 5.8%

Shares of ARGX opened at $891.32 on Friday. The firm has a market cap of $55.43 billion, a price-to-earnings ratio of 39.68, a PEG ratio of 1.29 and a beta of 0.47. The stock has a 50 day moving average of $794.90 and a 200-day moving average of $813.42. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The company had revenue of $1.31 billion during the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. On average, sell-side analysts predict that argenex SE will post 26.19 earnings per share for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.